You like this chart? Why or why not? Aspirin (cardio-protective dose only) Clopidagril (Plavix) Dabagatrin (Pradaxa) Dalteparin (Fragmin) Enoxaparin (Lovenox) Fondaparinux (Arixtra) Heparin Rivaroxaban (Xarelto) Ticlopidine (Ticlid) Ticagrelor (Brilinta) Prasugrel (Effient) Warfarin (Coumadin) Aspirin M M M M M M M M M M M Clopidagril (Plavix) M M M M M M M X X X M Dabagatrin … [continue reading]
Cephalosporins Are Not Created Equal
Posted on May 5, 2013 // 1 Comment
Just the other day I found where a pharmacist had discontinued cefepime off a patient's profile because a post-op order had included starting cefazolin post-op for three doses. This particular patient had pseudomonas positive cultures, and I scratched my head trying to figure out why the cefepime was stopped. Well... Our computer system flags cephalosporins as duplicates regardless of what generation and what is being treated. It is much too easy as a pharmacist to just allow the … [continue reading]
How One Patient Pharmacist Relationship Can Change Your Life
Posted on May 3, 2013 // 2 Comments
One patient can completely change your life. Brenda was her name. The website where there is an online cemetery mirroring how it looks in real life. There are moments in my career where I sit back and remember the impact she had on my life. Not only was she so vibrant (even over the phone) but she was also inspiring. We were in the same generation though my life was about a young man I had met (and later married) and hers was about fighting for her life. I was her pharmacist while … [continue reading]
ACCP: Update in Therapeutics (my thoughts)
Posted on April 23, 2013 // 11 Comments
Well, here I sit in the Reno airport waiting on my flight to LAS. My brain hurts a bit, but really enjoyed my stay at the Peppermill with my friend. She is taking the exam for the first time, and if you have been following me for any amount of time know its my second attempt at this certification. I feel what the in-person attendance vs the audio recordings can provide is the dedicated time to only listen to pharmacy all day for four days. I really have my days mixed up so forgive me if … [continue reading]
BCPS 2013: Some Pharmacoeconomics
Posted on April 10, 2013 // Leave a Comment
Pharmacoeconomics are on the test more than I would have thought. Some notes for you. Enjoy! Definitions A. Pharmacoeconomics—the description and analysis of the costs and consequences of pharmaceuticals and pharmaceutical services and its effects on individuals, health care systems, and society. These costs and consequences typically include both economic and humanistic assessments. 1. A division of outcomes research; however, NOT all outcomes research is pharmacoeconomic … [continue reading]
What is REMS?
Posted on April 9, 2013 // Leave a Comment
A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage a known or potential serious risk associated with a drug or biological product. A REMS will be required if the Food and Drug Administration (FDA) determines that a REMS is necessary to ensure the benefits of the drug or biological product outweigh its risks. A REMS can include a Medication Guide, Patient Package Insert, a communication plan, elements to assure safe use, and an implementation system. This resource center … [continue reading]
Comments